News
Mumbai Metro Line 3’s Phase 2A is in its final stage and waiting for approval from the Commissioner of ... Mumbai Metro Line 3’s Phase 2A is in its final stage and waiting for approval from the ...
Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an ...
The dyes that will be phased out in less than two years are FD&C Blue Nos. 1 and 2, FD&C Green No. 3, FD&C Red No. 40, FD&C Yellow Nos 5 and 6. In the coming months, the process will begin to ...
So said Roman Catholic Archbishop Fr Jason Gordon while delivering the Good Friday homily yesterday at The Cathedral of the Immaculate Conception, Independence Square, Port of Spain. He also ...
Additionally, a phase 3 trial evaluating the combination is planned, pending feedback from an FDA end-of-phase 2 meeting. “This is one of the strongest data set ever seen in an all-comer population of ...
Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial ...
Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...
Lilly's phase 3 trial showed that type 2 diabetes patients lost 16 pounds, or nearly 8% of their body weight, over 40 weeks. That compares favorably with Novo's injected drug Ozempic, where ...
Emerge is the third Phase 3 study of MM120 ODT, with the Voyage and Panorama studies in GAD already underway. “In our Phase 2b study, MADRS score improvements after a single MM120 100 µg dose ...
Emerge is the third Phase 3 study of MM120 ODT, with the Voyage and Panorama studies ... MindMed trades on NASDAQ under the symbol MNMD. Forward-Looking Statements Certain statements in this news ...
The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the product’s usage, BMS said Monday post … ...
PRINCETON, N.J., April 14, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback